NCT03368235View on ClinicalTrials.gov

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

November 12, 2019

Study Completion Date

November 12, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

AZD9567

oral OD SGRM administered as suspension

DRUG

Prednisolone

oral capsules of 20 mg prednisolone administered OD for two weeks

Trial Locations (5)

7512 KZ

Research Site, Enschede

6229 HX

Research Site, Maastricht

3584 CX

Research Site, Utrecht

413 45

Research Site, Gothenburg

221 85

Research Site, Lund

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY